Cardiol Therapeutics (CRDL) Competitors $1.36 -0.01 (-0.37%) As of 10:05 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRDL vs. ORKA, RAPP, RGNX, ERAS, FULC, ITOS, BNTC, RVNC, UPXI, and ABVXShould you be buying Cardiol Therapeutics stock or one of its competitors? The main competitors of Cardiol Therapeutics include Oruka Therapeutics (ORKA), Rapport Therapeutics (RAPP), REGENXBIO (RGNX), Erasca (ERAS), Fulcrum Therapeutics (FULC), iTeos Therapeutics (ITOS), Benitec Biopharma (BNTC), Revance Therapeutics (RVNC), Upexi (UPXI), and Abivax (ABVX). These companies are all part of the "pharmaceutical products" industry. Cardiol Therapeutics vs. Its Competitors Oruka Therapeutics Rapport Therapeutics REGENXBIO Erasca Fulcrum Therapeutics iTeos Therapeutics Benitec Biopharma Revance Therapeutics Upexi Abivax Cardiol Therapeutics (NASDAQ:CRDL) and Oruka Therapeutics (NASDAQ:ORKA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends. Which has more risk & volatility, CRDL or ORKA? Cardiol Therapeutics has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500. Comparatively, Oruka Therapeutics has a beta of -0.38, meaning that its share price is 138% less volatile than the S&P 500. Does the media favor CRDL or ORKA? In the previous week, Cardiol Therapeutics had 1 more articles in the media than Oruka Therapeutics. MarketBeat recorded 2 mentions for Cardiol Therapeutics and 1 mentions for Oruka Therapeutics. Cardiol Therapeutics' average media sentiment score of 0.93 beat Oruka Therapeutics' score of 0.63 indicating that Cardiol Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Cardiol Therapeutics Positive Oruka Therapeutics Positive Do analysts recommend CRDL or ORKA? Cardiol Therapeutics currently has a consensus price target of $8.00, indicating a potential upside of 490.41%. Oruka Therapeutics has a consensus price target of $40.38, indicating a potential upside of 256.98%. Given Cardiol Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cardiol Therapeutics is more favorable than Oruka Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardiol Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Oruka Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 3.20 Which has preferable earnings and valuation, CRDL or ORKA? Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Oruka Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCardiol TherapeuticsN/AN/A-$26.77M-$0.34-3.99Oruka TherapeuticsN/AN/A-$83.72M-$4.51-2.51 Is CRDL or ORKA more profitable? Oruka Therapeutics' return on equity of -25.66% beat Cardiol Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cardiol TherapeuticsN/A -209.63% -141.09% Oruka Therapeutics N/A -25.66%-23.39% Do insiders and institutionals have more ownership in CRDL or ORKA? 12.5% of Cardiol Therapeutics shares are held by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are held by institutional investors. 5.3% of Cardiol Therapeutics shares are held by insiders. Comparatively, 24.7% of Oruka Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. SummaryCardiol Therapeutics and Oruka Therapeutics tied by winning 7 of the 14 factors compared between the two stocks. Get Cardiol Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRDL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRDL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRDL vs. The Competition Export to ExcelMetricCardiol TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$111.99M$2.41B$5.47B$8.89BDividend YieldN/A1.80%5.36%4.13%P/E Ratio-3.999.2226.4119.70Price / SalesN/A622.46406.20108.23Price / CashN/A21.1625.8827.49Price / Book6.164.417.895.39Net Income-$26.77M$31.16M$3.15B$248.34M7 Day Performance1.12%0.12%0.54%0.65%1 Month Performance8.84%9.54%4.77%4.80%1 Year Performance-32.25%1.31%32.14%17.53% Cardiol Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRDLCardiol Therapeutics2.6562 of 5 stars$1.36-0.4%$8.00+490.4%-32.7%$111.99MN/A-3.9920Positive NewsGap UpORKAOruka Therapeutics2.6063 of 5 stars$10.90-6.7%$40.38+270.4%N/A$408.10MN/A-2.42N/ARAPPRapport Therapeutics2.2774 of 5 stars$10.88-0.4%$32.67+200.2%N/A$397.12MN/A-3.15N/APositive NewsRGNXREGENXBIO4.5097 of 5 stars$7.86-6.8%$31.63+302.4%-29.8%$394.26M$83.33M-2.53370Positive NewsERASErasca3.0049 of 5 stars$1.39+1.5%$4.57+228.9%-46.2%$393.77MN/A-2.24120News CoveragePositive NewsFULCFulcrum Therapeutics0.3456 of 5 stars$7.17+2.6%$6.29-12.3%+11.0%$387.03M$80M-102.41100ITOSiTeos Therapeutics3.2082 of 5 stars$10.11+1.5%$15.86+56.8%-32.8%$386.95M$35M-3.3390BNTCBenitec Biopharma1.6922 of 5 stars$14.57-0.3%$23.83+63.6%+67.4%$383.52M$80K0.0020High Trading VolumeRVNCRevance Therapeutics2.6963 of 5 stars$3.65flat$8.45+131.5%N/A$381.02M$234.04M-1.89500UPXIUpexi3.265 of 5 stars$10.00+8.1%$16.00+60.0%-58.7%$379.20M$26M0.00130Upcoming EarningsGap UpABVXAbivax2.4063 of 5 stars$6.11+2.3%$31.00+407.4%-42.1%$378.82MN/A0.0061Positive News Related Companies and Tools Related Companies ORKA Alternatives RAPP Alternatives RGNX Alternatives ERAS Alternatives FULC Alternatives ITOS Alternatives BNTC Alternatives RVNC Alternatives UPXI Alternatives ABVX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRDL) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiol Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiol Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
